CD8A and graft versus host disease: Specifically, loss of ASMase reduces acute inflammation, cytokine storm, CD8+ T-cell alloreactivity, diminishes GVHD target organs injury (liver, intestinal, and skin), and improves recipient morbidity and mortality after allo-HCT (50).